Frontiers in Immunology (Nov 2023)
Corrigendum: Alveolar macrophages in lung cancer: opportunities and challenges
- Cheng-Yen Chang,
- Dominique Armstrong,
- David B. Corry,
- David B. Corry,
- David B. Corry,
- David B. Corry,
- Farrah Kheradmand,
- Farrah Kheradmand,
- Farrah Kheradmand,
- Farrah Kheradmand
Affiliations
- Cheng-Yen Chang
- Department of Medicine, Baylor College of Medicine, Houston, TX, United States
- Dominique Armstrong
- Department of Medicine, Baylor College of Medicine, Houston, TX, United States
- David B. Corry
- Department of Medicine, Baylor College of Medicine, Houston, TX, United States
- David B. Corry
- Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States
- David B. Corry
- Biology of Inflammation Center, Baylor College of Medicine, Houston, TX, United States
- David B. Corry
- Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey Department of Veterans Affairs Medical Center, Houston, TX, United States
- Farrah Kheradmand
- Department of Medicine, Baylor College of Medicine, Houston, TX, United States
- Farrah Kheradmand
- Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States
- Farrah Kheradmand
- Biology of Inflammation Center, Baylor College of Medicine, Houston, TX, United States
- Farrah Kheradmand
- Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey Department of Veterans Affairs Medical Center, Houston, TX, United States
- DOI
- https://doi.org/10.3389/fimmu.2023.1328927
- Journal volume & issue
-
Vol. 14
Abstract
No abstracts available.Keywords
- tissue-resident alveolar macrophages
- smoking
- lung cancer
- immune checkpoint inhibitors
- tumor-associated macrophages
- tumor microenvironment
